ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Radiation Oncology

The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Pro Side

Kristin A. Higgins
on: April 22, 2021In: Radiation Oncology
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con - The Pro Side

The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeti... Read more


Deeper Dive Toxicity of Lung SBRT and Concurrent Immunotherapy Combinations: What We Know and What We Still Need to Learn

Sibo Tian, MD
+more
on: April 08, 2021In: Radiation Oncology
Deeper Dive Toxicity of Lung SBRT and Concurrent Immunotherapy Combinations: What We Know and What We
            Still Need to Learn

In Reference To: Tian S, Switchenko JM, Buchwald ZS, et al. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. Int J Radiat Oncol Biol Phys. 2020;108(1):304-313. Read more

The Dandelion Dilemma of Brain Metastases: Treating the Whole Lawn or the Weeds Separately

Hina Saeed, MD
+more
on: March 11, 2021In: Radiation Oncology
The Dandelion Dilemma of Brain Metastases: Treating the Whole Lawn or the Weeds Separately

Approximately, 40% to 60% of patients with small cell lung cancer (SCLC) develop brain metastases (BMs),1 ,2 ,3 and fewer than 15% survive beyond 2 years.4 ,5  Whereas upfront stereotactic […] Read more

PET vs. CT in Lung Cancer Surveillance: The ‘Pro’ Side from the Nuclear Medicine Perspective

Asha Kandathil, MD
on: February 27, 2021In: Radiation Oncology
PET vs. CT in Lung Cancer Surveillance: The ‘Pro’ Side from the Nuclear Medicine
            Perspective

A significant proportion of patients with stage I to III NSCLC or SCLC will have locoregional or distant metastases following curative-intent therapy. Studies have reported local recurrence rates of 22% […] Read more

Patient Perspectives on CT and PET Scans: Imaging Technology Provides Different Benefits, Drawbacks for Each Individual Patient

Ivy Elkins, MBA
+more
on: February 26, 2021In: Radiation Oncology
Patient Perspectives on CT and PET Scans: Imaging Technology Provides Different Benefits, Drawbacks for
            Each Individual Patient

For patients with metastatic lung cancer, frequent scans are a stark reality of living with cancer. Although most scans happen every 3 months, some clinical trials require scans more often […] Read more

FDG PET–CT Versus CT for Lung Cancer Surveillance: The "Con" Side

Palmi Shah, MD
on: February 25, 2021In: Radiation Oncology
FDG PET–CT Versus CT for Lung Cancer Surveillance: The "Con" Side

Lung cancer remains the leading cause of cancer-related deaths.1 Advances in early detection of lung cancer following the implementation of screening programs and the availability of newer therapies have increased […] Read more

SBRT Versus Surgery in the COVID-19 Era: What Has Changed and What Hasn't?

Suresh Senan, MRCP, FRCR, PhD
on: December 30, 2020In: Radiation Oncology
SBRT Versus Surgery in the COVID-19 Era: What Has Changed and What Hasn't?

Surgery is considered the preferred treatment in patients with lung cancer who are fit to undergo the procedure. Stereotactic radiotherapy (SBRT) is guideline recommended for patients who are unfit for […] Read more

Questions Remain Following Long-Term Results of the Phase II SABR-COMET Trial 

Ricardo Sales dos Santos, MD, PhD
on: November 23, 2020In: Radiation Oncology
Questions Remain Following Long-Term Results of the Phase II SABR-COMET Trial 

In Response To: Palma DA, Olson R, Harrow, S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. […] Read more

The Immune System: A New Organ at Risk in Lung Cancer Radiation Therapy?

Sibo Tian, MD
+more
on: October 26, 2020In: Radiation Oncology
The Immune System: A New Organ at Risk in Lung Cancer Radiation Therapy?

IN REFERENCE TO: Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of radiation dose to the host immune system on tumor control and survival for stage III […] Read more

Understanding the Promising Role of Stereotactic Ablative Radiotherapy in Treating Patients With Oligometastatic Disease

Arya Amini
+more
on: October 19, 2020In: Radiation Oncology
Understanding the Promising Role of Stereotactic Ablative Radiotherapy in Treating Patients With
            Oligometastatic Disease

The recently published long-term results of the SABR-COMET phase II trial have further invigorated treatment options for patients with oligometastatic cancer.1 The early results of the SABR-COMET trial published in […] Read more

1234
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy